Ospedale Pediatrico Bambino Gesù is a tertiary care academic children's hospital located in Rome that is under extraterritorial jurisdiction of the Holy See. As a tertiary children referral centre, the hospital provides over 20 specialties of healthcare through 10 pediatric departments.

There are 607 beds in Ospedale Pediatrico Bambino Gesu.

During the past decade, Ospedale Pediatrico Bambino Gesu conducted 154 clinical trials. In the 10-year time frame, 154 clinical trials started and 52 clinical trials were completed, i.e. on average, 33.8% percent of trials that started reached the finish line to date. In the past 5 years, 78 clinical trials started and 44 clinical trials were completed. i.e. 56.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ospedale Pediatrico Bambino Gesu" #1 sponsor was "Bambino Gesù Hospital and Research Institute" with 16 trials, followed by "Hoffmann-La Roche" with 10 trials sponsored, "PTC Therapeutics" with 10 trials sponsored, "Takeda" with 8 trials sponsored and "Amgen" with 8 trials sponsored. Other sponsors include 142 different institutions and companies that sponsored additional 91 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ospedale Pediatrico Bambino Gesu" #1 collaborator was "CRISPR Therapeutics" with 3 trials as a collaborator, "Novartis" with 3 trials as a collaborator, "Takeda Development Center Americas, Inc." with 3 trials as a collaborator, "Australian & New Zealand Children's Haematology/Oncology Group" with 2 trials as a collaborator and "Baxalta Innovations GmbH, now part of Shire" with 2 trials as a collaborator. Other collaborators include 132 different institutions and companies that were collaborators in the rest 113 trials.

According to Clinical.Site data, the most researched conditions in "Ospedale Pediatrico Bambino Gesu" are "Cystic Fibrosis" (9 trials), "Duchenne Muscular Dystrophy" (6 trials), "Genetic Diseases, Inborn" (5 trials), "Hemoglobinopathies" (5 trials) and "Thalassemia" (5 trials). Many other conditions were trialed in "Ospedale Pediatrico Bambino Gesu" in a lesser frequency.

Most popular intervention types in "Ospedale Pediatrico Bambino Gesu" are "Drug" (138 trials), "Biological" (24 trials), "Other" (24 trials), "Device" (9 trials) and "Procedure" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (38 trials), "Cyclophosphamide" (7 trials), "Etoposide" (7 trials), "Ataluren" (6 trials) and "Tocilizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Ospedale Pediatrico Bambino Gesu" are 185 trials for "All" genders, 11 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are 85 active trials in "Ospedale Pediatrico Bambino Gesu". 2 are not yet recruiting, 49 are recruiting, 30 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 84 completed trials in Ospedale Pediatrico Bambino Gesu, 1 suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Ospedale Pediatrico Bambino Gesu, 36 "Phase 1" clinical trials were conducted, 69 "Phase 2" clinical trials and 90 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 12 trials that are defined as “Not Applicable".

Ospedale Pediatrico Bambino Gesu has several departments that took part in Clinical trials: "Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS" - 5 trials, "IRCCS Ospedale Pediatrico Bambino Gesù; U.O. Malattie Neuromuscolari e Neurodegenerative" - 3 trials, "Ospedale Pediatrico Bambino Gesu; U.O. Di Nefrologia E Dialisi" - 2 trials, "Dipartimento Pediatrico Universitario-Ospedaliero Endocrinologia" - 2 trials, "U.O Malattie Neuromuscolari e Neurodegenerative - IRCCS Ospedale Pediatrico Bambino Gesu" - 2 trials